- Home
- JRS vs CYBN Comparison
JRS vs CYBN Comparison
Compare JRS & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- CYBN
- Stock Information
- Founded
- JRS 2001
- CYBN 2019
- Country
- JRS United States
- CYBN Canada
- Employees
- JRS N/A
- CYBN N/A
- Industry
- JRS Finance/Investors Services
- CYBN Pharmaceuticals and Biotechnology
- Sector
- JRS Finance
- CYBN Health Care
- Exchange
- JRS Nasdaq
- CYBN Nasdaq
- Market Cap
- JRS 236.9M
- CYBN 127.3M
- IPO Year
- JRS N/A
- CYBN N/A
- Fundamental
- Price
- JRS $7.96
- CYBN $6.59
- Analyst Decision
- JRS
- CYBN Strong Buy
- Analyst Count
- JRS 0
- CYBN 4
- Target Price
- JRS N/A
- CYBN $86.00
- AVG Volume (30 Days)
- JRS 86.6K
- CYBN 275.3K
- Earning Date
- JRS 01-01-0001
- CYBN 06-25-2025
- Dividend Yield
- JRS 8.87%
- CYBN N/A
- EPS Growth
- JRS N/A
- CYBN N/A
- EPS
- JRS N/A
- CYBN N/A
- Revenue
- JRS N/A
- CYBN N/A
- Revenue This Year
- JRS N/A
- CYBN N/A
- Revenue Next Year
- JRS N/A
- CYBN N/A
- P/E Ratio
- JRS N/A
- CYBN N/A
- Revenue Growth
- JRS N/A
- CYBN N/A
- 52 Week Low
- JRS $5.95
- CYBN $4.81
- 52 Week High
- JRS $8.00
- CYBN $14.44
- Technical
- Relative Strength Index (RSI)
- JRS 55.28
- CYBN 47.25
- Support Level
- JRS $7.84
- CYBN $6.05
- Resistance Level
- JRS $8.09
- CYBN $7.11
- Average True Range (ATR)
- JRS 0.16
- CYBN 0.43
- MACD
- JRS 0.06
- CYBN -0.03
- Stochastic Oscillator
- JRS 82.00
- CYBN 30.00
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.